What is the half-life of PT-141 (Bremelanotide)?

PT-141 (Bremelanotide) has a half-life of ~2.7 hours, which is why it's typically administered as needed, at least 45 minutes before anticipated activity for optimal therapeutic effect.

How do I reconstitute PT-141 (Bremelanotide)?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Phase 3

PT-141 (Bremelanotide)

Also known as: Bremelanotide, Vyleesi, PT141

Overview

Key Facts

Primary Goal: An FDA-approved melanocortin receptor agonist originally derived from Melanotan II, developed specifically for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women

An FDA-approved melanocortin receptor agonist originally derived from Melanotan II, developed specifically for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, it acts centrally on the nervous system to enhance sexual desire rather than targeting vascular mechanics. Half-Life ~2.7 hours Typical Dose 500–1750 mcg Frequency as needed, at least 45 minutes before anticipated activity Cycle Length As needed (no more than once per 24 hours, max 8 doses per month per FDA labeling)

Dosing Information

Half-Life

~2.7 hours

Typical Dose

500–1750 mcg

Frequency

as needed, at least 45 minutes before anticipated activity

Cycle Length

As needed (no more than once per 24 hours, max 8 doses per month per FDA labeling)

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Phase 3

Bremelanotide was approved by the FDA in June 2019 under the brand name Vyleesi for HSDD in premenopausal women, following two Phase III RECONNECT trials. These studies showed statistically significant improvements in sexual desire and reductions in distress compared to placebo. Earlier Phase II research in men also demonstrated pro-erectile effects, though development focused on the female indication. It remains the only FDA-approved on-demand treatment for HSDD.